GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) » Definitions » Gross Profit

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Gross Profit : E£906 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Gross Profit?

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's gross profit for the three months ended in Dec. 2023 was E£254 Mil. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was E£906 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's gross profit for the three months ended in Dec. 2023 was E£254 Mil. Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Revenue for the three months ended in Dec. 2023 was E£534 Mil. Therefore, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Margin % for the quarter that ended in Dec. 2023 was 47.57%.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents had a gross margin of 47.57% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 6 years, the highest Gross Margin % of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents was 50.34%. The lowest was 45.37%. And the median was 46.82%.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Gross Profit Historical Data

The historical data trend for Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Gross Profit Chart

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 405.57 446.59 577.53 720.04 905.92

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 180.82 178.75 207.97 265.09 254.10

Competitive Comparison of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Profit distribution charts can be found below:

* The bar in red indicates where Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Profit falls into.



Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=1922.351 - 1016.436
=906

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=534.192 - 280.093
=254

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£906 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=254 / 534.192
=47.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents  (CAI:RMDA) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents had a gross margin of 47.57% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents Gross Profit Related Terms

Thank you for viewing the detailed overview of Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Second Industrial Zone, Sixth of October City, Giza, EGY
Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents is a pharmaceutical company. It is engaged in the manufacture and sale of branded generic pharmaceutical products nutraceuticals, cosmeceuticals, food supplements, medical devices, and veterinary products. The firm is engaged in therapeutic areas namely systemic anti-infectives, alimentary tract and metabolism, genitourinary system and sex hormones, cardiovascular system, nervous system, and blood and blood-forming organs.

Tenth Of Ramadan For Pharmaceutical Industries And Diagnostic Reagents (CAI:RMDA) Headlines

No Headlines